DPD and UGT1A1 deficiency in colorectal cancer patients receiving triplet chemotherapy with fluoropyrimidines, oxaliplatin and irinotecan.

doi:10.1111/bcp.12631

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Community

Back to search

Article

DPD and UGT1A1 deficiency in colorectal cancer patients receiving triplet chemotherapy with fluoropyrimidines, oxaliplatin and irinotecan.

British journal of clinical pharmacology - 1 Sept 2015

Falvella Felicia Stefania, Cheli Stefania, Martinetti Antonia, Mazzali Cristina, Iacovelli Roberto, Maggi Claudia, Gariboldi Manuela, Pierotti Marco Alessandro, Di Bartolomeo Maria, Sottotetti Elisa, Mennitto Roberta, Bossi Ilaria, de Braud Filippo, Clementi Emilio, Pietrantonio Filippo

Abstract excerpt

AIMS: Triplet chemotherapy with fluoropyrimidines, oxaliplatin and irinotecan is a standard therapy for metastatic colorectal cancer (CRC). Single nucleotide polymorphisms (SNPs) in DPYD and UGT1A1 influence fluoropyrimdines and irinotecan adverse events (AEs). Low frequency DPYD variants (c.1905 + 1G > A, c.1679 T > G, c.2846A > T) are validated but more frequent ones (c.496A > G, c.1129-5923C > G and c.1896 T >...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antineoplastic Combined Chemotherapy Protocols

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Camptothecin

Share to Dihydrouracil Dehydrogenase (NADP)

Share to Fluorouracil

Share to Glucuronosyltransferase

Share to Leucovorin

Share to MicroRNAs

Share to Organoplatinum Compounds

Source

Open in PubMed Open full text

Identifiers

PMID: 25782327
DOI: 10.1111/bcp.12631
PMCID: PMC4574842

Genes

DPYD

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

DPD and UGT1A1 deficiency in colorectal cancer patients receiving triplet chemotherapy with fluoropyrimidines, oxaliplatin and irinotecan.PMID 25782327Read ↗

Examination of multiple UGT1A and DPYD polymorphisms has limited ability to predict the toxicity and efficacy of metastatic colorectal cancer treated with irinotecan-based chemotherapy: a retrospective analysis.Semantic proximity Read ↗

DPYD polymorphisms c.496A>G , c.2194G>A and c.85T>C and risk of severe adverse drug reactions in patients treated with fluoropyrimidine-based protocolsSemantic proximity Read ↗

DPYD polymorphisms c.496A>G, c.2194G>A and c.85T>C and risk of severe adverse drug reactions in patients treated with fluoropyrimidine-based protocols.Semantic proximity Read ↗

Predictive value of clinical toxicities of chemotherapy with fluoropyrimidines and oxaliplatin in colorectal cancer by DPYD and GSTP1 gene polymorphismsSemantic proximity Read ↗

Genotyping of DPYD and UGT1A1 in Brazilian oncological patients: applying pharmacogenomics in an admixed population.Semantic proximity Read ↗

MIR27A rs895819 TC genotype increases risk of fluoropyrimidine-induced severe toxicity independently of DPYD variations.Semantic proximity Read ↗

Correlation between DPYD gene variation and KRAS wild type status in colorectal cancer.Semantic proximity Read ↗

Rs895819 in MIR27A improves the predictive value of DPYD variants to identify patients at risk of severe fluoropyrimidine-associated toxicity.Semantic proximity Read ↗

Predictive value of clinical toxicities of chemotherapy with fluoropyrimidines and oxaliplatin in colorectal cancer by DPYD and GSTP1 gene polymorphisms.Semantic proximity Read ↗

The clinical relevance of multiple DPYD polymorphisms on patients candidate for fluoropyrimidine based-chemotherapy. An Italian case-control studySemantic proximity Read ↗

The Genotype for DPYD Risk Variants in Patients With Colorectal Cancer and the Related Toxicity Management Costs in Clinical PracticeSemantic proximity Read ↗

A predictive model for life-threatening fluoropyrimidine toxicity based on DPYD sequencing in colorectal cancer.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.